Catalyst
Slingshot members are tracking this event:
Corcept's (CORT) Phase 1 Study of Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer Completed
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CORT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 20, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mifepristone, Eribulin, Metastatic Triple Negative Breast Cancer
